nach oben

Erschienen in:

01.09.2014 | Original Communication

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome

verfasst von: Tomas Uher, Jana Blahova-Dusankova, Dana Horakova, Niels Bergsland, Michaela Tyblova, Ralph H. B. Benedict, Tomas Kalincik, Deepa P. Ramasamy, Zdenek Seidl, Jesper Hagermeier, Manuela Vaneckova, Jan Krasensky, Eva Havrdova, Robert Zivadinov

Erschienen in: Journal of Neurology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Cognitive impairment (CI) may occur in clinically isolated syndrome (CIS) patients. While the relationship between CI and magnetic resonance imaging (MRI) has been investigated extensively in multiple sclerosis (MS), MRI correlates of CI in CIS patients are unknown. To investigate the evolution of CI and to determine brain MRI structural correlates associated with CI in CIS patients. This prospective 24-month observational study examined 81 CIS patients treated with 30 µg of intramuscular interferon beta 1a once a week. MRI acquisition and neuropsychological (NP) assessment were performed at baseline, 6, 12 and 24 months. Participants were tested with Czech-validated version of Minimal Assessment of Cognitive Function in MS battery and MRI measures of lesion activity and burden, and global, tissue-specific and regional brain atrophy were performed. Over 24 months, 36 CIS patients developed clinically definite MS (CDMS). CI was observed in 10 (12.3 %) CIS patients at baseline and at the 24 months follow-up. Eight CIS patients changed their CI status over the follow-up (four improved and four worsened). No significant difference in development of CI was detected between stable CIS patients and those who developed CDMS. In multivariate regression and mixed-effect model analyses, no significant relationship was found between NP and MRI parameters. The lack of significant relationship between MRI metrics and cognition in this group of CIS patients could be attributed to several factors including the cognitive reserve, effect of disease-modifying therapy and relatively short follow-up period.

Benedict RH, Zivadinov R (2011) Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 7:332–342CrossRefPubMed

Morrow SA, Drake A, Zivadinov R, Munschauer F, Weinstock-Guttman B et al (2010) Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol 24:1131–1145CrossRefPubMed

Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E (2012) Cost of multiple sclerosis in the Czech Republic: the COMS study. Multiple Scler 18:662–668CrossRef

Langdon DW (2011) Cognition in multiple sclerosis. Curr Opin Neurol 24:244–249CrossRefPubMed

Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691CrossRefPubMed

Glanz BI, Holland CM, Gauthier SA, Amunwa EL, Liptak Z et al (2007) Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Multiple Scler 13:1004–1010CrossRef

Viterbo RG, Iaffaldano P, Trojano M (2013) Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. J Neurol Sci 330:56–60CrossRefPubMed

Feuillet L, Reuter F, Audoin B, Malikova I, Barrau K et al (2007) Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Scler 13:124–127CrossRef

Benedict RH, Fischer JS, Archibald CJ, Arnett PA, Beatty WW et al (2002) Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 16:381–397CrossRefPubMed

10.

Zipoli V, Goretti B, Hakiki B, Siracusa G, Sorbi S et al (2010) Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Multiple Scler 16:62–67CrossRef

11.

Reuter F, Zaaraoui W, Crespy L, Faivre A, Rico A et al (2011) Cognitive impairment at the onset of multiple sclerosis: relationship to lesion location. Multiple Scler J 17(6):755–758CrossRef

12.

Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M et al (2013) Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS ONE 8:e71058PubMedCentralCrossRefPubMed

13.

Potagas C, Giogkaraki E, Koutsis G, Mandellos D, Tsirempolou E et al (2008) Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci 267:100–106CrossRefPubMed

14.

Achiron A, Barak Y (2003) Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 74:443–446PubMedCentralCrossRefPubMed

15.

Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH et al (2012) Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Multiple Scler 18:1466–1471CrossRef

16.

Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L (1989) Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 39:161–166CrossRefPubMed

17.

Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM et al (2001) A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70:773–780PubMedCentralCrossRefPubMed

18.

Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M et al (2007) Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 64:1157–1161CrossRefPubMed

19.

Benedict RH, Bruce JM, Dwyer MG, Abdelrahman N, Hussein S et al (2006) Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 63:1301–1306CrossRefPubMed

20.

Houtchens MK, Benedict RH, Killiany R, Sharma J, Jaisani Z et al (2007) Thalamic atrophy and cognition in multiple sclerosis. Neurology 69:1213–1223CrossRefPubMed

21.

Benedict RH, Hulst HE, Bergsland N, Schoonheim MM, Dwyer MG et al (2013) Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Multiple Scler 19:1478–1484CrossRef

22.

Schoonheim MM, Popescu V, Rueda Lopes FC, Wiebenga OT, Vrenken H et al (2012) Subcortical atrophy and cognition: sex effects in multiple sclerosis. Neurology 79:1754–1761CrossRefPubMed

23.

Reuter F, Zaaraoui W, Crespy L, Faivre A, Rico A et al (2011) Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis. J Neurol Neurosurg Psychiatry 82:1157–1159CrossRefPubMed

24.

Summers M, Swanton J, Fernando K, Dalton C, Miller DH et al (2008) Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry 79:955–958CrossRefPubMed

25.

Zivadinov R, Havrdova E, Bergsland N, Tyblova M, Hagemeier J et al (2013) Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 268:831–841CrossRefPubMed

26.

Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML et al (2008) Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 79:1236–1244CrossRefPubMed

27.

Kalincik T, Vaneckova M, Tyblova M, Krasensky J, Seidl Z et al (2012) Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS ONE 7:e50101PubMedCentralCrossRefPubMed

28.

Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Qu J et al (2013) Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS ONE 8:e53996PubMedCentralCrossRefPubMed

29.

Browne RW, Weinstock-Guttman B, Horakova D, Zivadinov R, Bodziak ML et al (2014) Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2013-307106

30.

Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc JINS 12:549–558CrossRefPubMed

31.

Dusankova JB, Kalincik T, Havrdova E, Benedict RH (2012) Cross cultural validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS). Clin Neuropsychol 26:1186–1200CrossRefPubMed

32.

Dwyer MG, Bergsland N, Zivadinov R (2013) Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. Neuroimage 90:207–217

33.

Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489CrossRefPubMed

34.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846CrossRefPubMed

35.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302PubMedCentralCrossRefPubMed

36.

Feinstein A, Kartsounis LD, Miller DH, Youl BD, Ron MA (1992) Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry 55:869–876PubMedCentralCrossRefPubMed

37.

Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M et al (2004) Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 63:89–93CrossRefPubMed

38.

Sepulcre J, Vanotti S, Hernandez R, Sandoval G, Caceres F et al (2006) Cognitive impairment in patients with multiple sclerosis using the brief repeatable battery-neuropsychology test. Multiple Scler 12:187–195CrossRef

39.

Sumowski JF, Leavitt VM (2013) Cognitive reserve in multiple sclerosis. Multiple Scler 19:1122–1127CrossRef

40.

Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA et al (2000) Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 48:885–892CrossRefPubMed

41.

Benedict RH, Morrow SA, Weinstock Guttman B, Cookfair D, Schretlen DJ (2010) Cognitive reserve moderates decline in information processing speed in multiple sclerosis patients. J Int Neuropsychol Soc JINS 16:829–835CrossRefPubMed

42.

Amato MP, Razzolini L, Goretti B, Stromillo ML, Rossi F et al (2013) Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. Neurology 80:1728–1733CrossRefPubMed

43.

Jonsson A, Andresen J, Storr L, Tscherning T, Sorensen PS et al (2006) Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study. J Neurol Sci 245:77–85CrossRefPubMed

44.

Glanz BI, Healy BC, Hviid LE, Chitnis T, Weiner HL (2012) Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry 83:38–43CrossRefPubMed

45.

Bartley AJ, Jones DW, Weinberger DR (1997) Genetic variability of human brain size and cortical gyral patterns. Brain J Neurol 120(Pt 2):257–269CrossRef

46.

Sumowski JF, Chiaravalloti N, Wylie G, Deluca J (2009) Cognitive reserve moderates the negative effect of brain atrophy on cognitive efficiency in multiple sclerosis. J Int Neuropsychol Soc JINS 15:606–612CrossRefPubMed

47.

Morrow SA, Weinstock-Guttman B, Munschauer FE, Hojnacki D, Benedict RH (2009) Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Multiple Scler 15:998–1005CrossRef

Titel: Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome
verfasst von: Tomas Uher
Jana Blahova-Dusankova
Dana Horakova
Niels Bergsland
Michaela Tyblova
Ralph H. B. Benedict
Tomas Kalincik
Deepa P. Ramasamy
Zdenek Seidl
Jesper Hagermeier
Manuela Vaneckova
Jan Krasensky
Eva Havrdova
Robert Zivadinov
Publikationsdatum: 01.09.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 9/2014
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-014-7413-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Reducing central nervous system complications associated with the human immunodeficiency virus

Short rapid steps to provoke freezing of gait in Parkinson’s disease

Erratum to: Time intervals from aneurysmal subarachnoid hemorrhage to treatment and factors contributing to delay

Population-based incidence and 5-year survival for hospital-admitted traumatic brain and spinal cord injury, Western Australia, 2003–2008

Johann Hoffmann (1857–1919)